Resources

February 06, 2023

White paper: A proprietary mammalian suspension technology for scalable rAAV production: The Pro10™ cell line

Discover how the HEK293-derived Pro10™ cell line accelerates AAV vector production. This whitepaper explores a scalable, animal component-free platform that reduces process development time and costs, meeting growing clinical and commercial demands for gene therapies.

Download

Explore more

Insights

Harnessing AI for Faster and More Efficient Development & Manufacturing of Life-Changing Gene Therapies

Authors: María Iglesias, Head of Digital & IT Jens Keune, Data Science & Digital Product Manager Abstract As the biopharmaceutical landscape evolves, the integration of Artificial Intelligence (AI) into gene therapy manufacturing is increasingly...

July 28, 2025

Resources

Webinar: Outsourced Pharma Capacity Update July 2025 - Fill/Finish

“May you live in interesting times.” Viralgen Chief Commercial Officer Andy Holt invokes that apocryphal “half-blessing, half-curse” as he opens his recent appearance on Outsourced Pharma Capacity Update. Andy identifies some of the key dynamics...